Journal of lipid and atherosclerosis
Metabolic and Clinical Outcomes of Combined Pitavastatin and Valsartan Therapy in Patients With Acute Myocardial Infarction: A Multicenter Prospective Observational Study
By Cho KH, Hong YJ, Lee SR and 10 others.
Abstract
Objective
We evaluated the efficacy and safety of combined pitavastatin and valsartan therapy in patients with acute myocardial infarction.
Methods
This non-interventional, multicenter, prospective observational study included 836 patients receiving combined pitavastatin and valsartan (80 mg) with 48 weeks of follow-up. Co-primary outcomes were major adverse cardiovascular events (MACEs) and changes in metabolic profiles.
Results
Among 698 patients (mean age 61.8±12.1 years; 81.4% male) treated with pitavastatin/valsartan 2/80 mg or 4/80 mg, 15 MACEs occurred at 48 weeks (15/698, 2.1%). The mean (standard deviation) changes in fasting blood glucose and glycated hemoglobin from baseline to 48 weeks were -11.4±45.0 mg/dL (p=0.467) and -0.17±0.29% (p=0.165) for the 2/80 mg group, and -7.9±46.2 mg/dL (p=0.043) and -0.06±1.07% (p=0.181) for the 4/80 mg group, respectively. The mean (standard deviation) reductions in low-density lipoprotein cholesterol from baseline to 48 weeks were -27.9±24.7 mg/dL (p=0.006) for 2/80 mg and -29.9±38.1 mg/dL (p<0.001) for 4/80 mg. No serious adverse drug reactions were observed except for one case of chest pain in one patient.